載入...
Targeted therapy in Advanced Bladder cancer- what have we learned?
Urothelial carcinoma (UC) is the second most common genitourinary malignancy in the United States. In the metastatic setting, cisplatin-based chemotherapy results in a median overall survival (OS) of 12–15 months and remains the only standard of care for this disease. Despite advances in the treatme...
Na minha lista:
| 發表在: | Urol Clin North Am |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4939834/ https://ncbi.nlm.nih.gov/pubmed/25882566 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ucl.2015.01.006 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|